Hospital Pedro Hispano — Clinical Trial Site

36 Registered trials

18 Currently recruiting

Organisation

Hospital Pedro Hispano

Location

Matosinhos, Portugal

Identifier

ORG-100028535

Address

Rua Doutor Eduardo Torres, 4464-513, Portugal

Departments

Cardiology
Cardiology department
Departamento de Neurologia
Department of Neurology
Early Phase Clinical Trials Unit | ULSM+BlueClinical
Endocrinology
Gastroenterology Department and Advanced Endoscopy Center ‘Carlos Moreira da Silva´
Hospital Pedro Hispano, Immunoallergology
Internal medicine
Internal Medicine Department
NA
nephrology department
Neurology
Neurology Department
Neurology Unit
Oncology
Otorhinolaryngology service
Pneumology
Pulmonology
Serviço de Nefrologia
Serviço de Neurologia
Serviço de Oncologia
Serviço de Pneumologia
Serviço Neurologia
Unidade Local de Saude de Matosinhos-Hospital Pedro Hispano
Unidade Local de Saude de Matosinhos-Hospital Pedro Hispano( #1)
Unidade Local de Saúde de Matosinhos, E.P.E., Hospital Pedro Hispano
Unidade Local Saude Matosinhos, EPE, Pedro Hispano
Urology

Clinical trials at this site (36)

Search interface

A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents with Severe Uncontrolled Asthma (SOLAIRIA-1) Pending

2025-521950-41-00 severe uncontrolled asthma 5
An extension study to investigate the long-term safety and tolerability of itepekimab in adult participants with inadequately controlled chr… Pending

2025-522983-33-00 Chronic rhinosinusitis with nasal polyps 5
A Phase 1 Study of AIR-001 in Adults with AATD. Pending

2025-523558-14-00 Alpha-1 Antitrypsin Deficiency 1
A Phase 3 Study of Orelabrutinib in Patients with Primary Progressive Multiple Sclerosis Pending

2025-524316-11-00 Primary Progressive Multiple Sclerosis (PPMS) 5
Trial to confirm efficacy, safety, and clinical impact between the bacterial mucosal immunotherapy compared with placebo in women with local… Pending

2025-524377-16-00 Recurrent Non-Complicated Urinary Tract Infections (rUT 5
AMAZE 8: A research study investigating how well the medicine NNC0487-0111 compared to semaglutide helps people with excess body weight and … Recruiting

2024-520446-31-00 Participants with overweight or obesity, and type 2 dia 5 2026-05-27
A Clinical Trial to Compare the Effectiveness and Safety of RO7771950 in Combination with Trastuzumab and Capecitabine, Versus Tucatinib in … Recruiting

2025-524498-17-00 Pretreated Unresectable Locally Advanced or Metastatic 10 2026-05-08
A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults (BARICADE-DELAY) Recruiting

2025-521797-34-00 Diabetes Mellitus, Type 1 5 2026-01-20
AFFIRM: A Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients with Pri… Recruiting

2024-516525-31-01 Primary Biliary Cholangitis 5 2025-07-14
Long-term safety and efficacy study of riliprubart in participants with CIDP Recruiting

2024-517032-22-00 Immune system diseases. 5 2025-06-10
Efficacy and safety study of frexalimab (SAR441344) in adults with relapsing forms of multiple sclerosis Recruiting

2023-504358-36-00 multiple sclerosis 5 2024-10-17
A study to test whether different doses of BI 764532 help people with small cell lung cancer or other neuroendocrine cancers Recruiting

2023-504247-13-00 Large cell neuroendocrine carcinoma 4 2023-10-17
ZENITH: Zilebesiran in Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk … Recruiting

2025-522960-34-00 Established cardiovascular disease 5 2026-02-09
Saccharomyces boulardii CNCM I-745 in Irritable Bowel Syndrome. Recruiting

2024-520276-10-00 Non-constipated Irritable Bowel Syndrome (IBS) 5 2025-09-04
Safety and Efficacy of Intravenous Thrombolysis in Patients with Ischemic Stroke on Treatment with Direct Oral Anticoagulants: DO-IT – The D… Recruiting

2024-515561-34-01 Acute ischemic stroke with recent ingestion of direct o 6 2025-08-04
A study to evaluate the efficacy and safety of frexalimab, brivekimig or rilzabrutinib in participants aged 16 to 75 years with primary foca… Recruiting

2024-511775-15-00 Immune system diseases 4 2025-01-17
A study to determine if BHV-7000 is safe in adults with refractory focal onset epilepsy Recruiting

2023-508813-18-00 Refractory Focal Onset Epilepsy 4 2024-12-18
A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy Recruiting

2023-508811-21-00 Refractory Focal Onset Epilepsy 10 2024-09-25
A follow-up study to test long-term treatment with BI 1015550 in people with pulmonary fibrosis who took part in a previous study with BI 10… Recruiting

2023-507353-15-00 idiopathic pulmonary fibrosis (IPF) 5 2024-09-10
A study to test the effects and safety of riliprubart in people with chronic inflammatory demyelinating polyneuropathy (CIDP) for which the … Recruiting

2023-506503-26-00 Polyneuropathy, Inflammatory Demyelinating, Chronic 5 2024-07-31
A study to investigate long-term safety and tolerability of tolebrutinib in participants with multiple sclerosis Recruiting

2023-503631-18-01 Nervous system diseases 5 2024-05-20
A clinical study to compare MK-2870 with pembrolizumab to pembrolizumab alone in people with lung cancer (MK-2870-007) Recruiting

2023-503376-24-00 Metastatic non-small cell lung cancer (NSCLC) 5 2024-03-20
RECOVERY Recruiting

2023-507441-29-00 Pneumonia 5 2024-02-29
A Phase 3 study to assess the efficacy, safety, and tolerability of itepekimab (antiIL33 mAb) in participants with inadequately-controlled… Ended

2024-516814-39-00 Chronic rhinosinusitis with nasal polyps 5 2025-05-20